ADC Therapeutics (NYSE:ADCT) Receives “Outperform” Rating from Royal Bank Of Canada

ADC Therapeutics (NYSE:ADCT)‘s stock had its “outperform” rating restated by investment analysts at Royal Bank Of Canada in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $6.00 price target on the stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 59.40% from the company’s previous close.

A number of other brokerages also recently issued reports on ADCT. Weiss Ratings reissued a “sell (d-)” rating on shares of ADC Therapeutics in a research report on Monday, April 20th. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of ADC Therapeutics in a research report on Tuesday. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.00.

ADC Therapeutics Stock Performance

Shares of NYSE ADCT traded up $0.08 during mid-day trading on Tuesday, hitting $3.76. The stock had a trading volume of 328,842 shares, compared to its average volume of 850,343. ADC Therapeutics has a 1 year low of $1.23 and a 1 year high of $4.98. The business has a 50 day moving average price of $4.04 and a two-hundred day moving average price of $3.96. The firm has a market cap of $478.74 million, a P/E ratio of -3.15 and a beta of 1.83.

ADC Therapeutics (NYSE:ADCT) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The business had revenue of $20.85 million for the quarter, compared to analyst estimates of $19.99 million. During the same quarter in the prior year, the firm posted ($0.36) earnings per share. Equities research analysts predict that ADC Therapeutics will post -0.82 EPS for the current fiscal year.

Insider Activity at ADC Therapeutics

In other news, major shareholder Redmile Group, Llc sold 2,634,506 shares of the business’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $3.28, for a total transaction of $8,641,179.68. Following the sale, the insider owned 12,666,731 shares in the company, valued at approximately $41,546,877.68. The trade was a 17.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders have sold 5,880,415 shares of company stock worth $19,641,067. Insiders own 5.40% of the company’s stock.

Institutional Trading of ADC Therapeutics

A number of hedge funds have recently modified their holdings of ADCT. AQR Capital Management LLC boosted its holdings in shares of ADC Therapeutics by 411.1% during the 1st quarter. AQR Capital Management LLC now owns 201,170 shares of the company’s stock valued at $284,000 after buying an additional 161,808 shares in the last quarter. Creative Planning bought a new stake in shares of ADC Therapeutics during the 2nd quarter valued at $96,000. Nantahala Capital Management LLC bought a new stake in shares of ADC Therapeutics during the 2nd quarter valued at $6,074,000. Bank of America Corp DE boosted its holdings in shares of ADC Therapeutics by 22.1% during the 2nd quarter. Bank of America Corp DE now owns 2,199,059 shares of the company’s stock valued at $5,893,000 after buying an additional 397,905 shares in the last quarter. Finally, Corient Private Wealth LLC bought a new stake in shares of ADC Therapeutics during the 2nd quarter valued at $959,000. Institutional investors own 41.10% of the company’s stock.

ADC Therapeutics News Summary

Here are the key news stories impacting ADC Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and set an $8.00 price target (roughly +112% upside vs. current levels), which can attract demand from growth-oriented investors and supports higher valuation expectations. Benzinga
• Positive Sentiment: Company reiterated near-term clinical catalysts: LOTIS-5 Phase 3 topline data expected in Q2 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end — clear potential binary catalysts that could move the stock on positive or negative readouts. PR Newswire: Q1 2026 Results & Operational Updates
• Positive Sentiment: Q1 reported net product revenue of about $20.0M and cash & equivalents of $231M with an expected runway at least into 2028 — this reduces near-term financing risk and supports commercial execution through upcoming readouts. PR Newswire: Q1 2026 Results & Operational Updates
• Neutral Sentiment: Management held an earnings conference call and published slide materials — useful for detail on commercial uptake, spend cadence and timelines but not immediately catalytic absent new guidance. Q1 Slide Deck / Press Release
• Neutral Sentiment: Earnings call transcripts are available for those wanting management color on commercial trends and the timing/details for the LOTIS programs. These are informational but unlikely to move the stock by themselves. Yahoo Finance: Q4/Q1 Transcripts
• Negative Sentiment: Q1 EPS missed consensus: reported loss of $0.21 vs. consensus -$0.19 (though an improvement vs. prior year -$0.36). The EPS miss could temper enthusiasm until clinical readouts validate growth expectations. Zacks: Q1 Loss, Beats Revenue Estimates

About ADC Therapeutics

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.